title: Bile acids suppress the secretion of very-low-density lipoprotein by human hepatocytes in primary culture.
abstract: The existence of a relationship between bile acid and triacylglycerol metabolism in humans has been established, but the underlying mechanism and its physiological relevance have remained unclear. We have studied the effects of bile acids on the secretion of very-low-density lipoprotein (VLDL)-associated triacylglycerol, using [3H]glycerol labeling technique, and apolipoprotein B (apoB) in human hepatocytes in primary culture. Human hepatocytes secrete nascent VLDL with an average diameter of about 40 nm. Lipid composition of the particles resembles that reported for plasma VLDL, with the exception of a markedly lower cholesterylester content. In 24-hour cultured human hepatocytes, physiological (i.e., portal) concentrations of taurocholic acid (10 to 200 mumol/L) suppressed [3H]triacylglycerol secretion dose dependently. The degree of inhibition highly correlated (r = .87, P < .01) with taurocholic acid content of the cells of different preparations (n = 7). ApoB secretion was inhibited by taurocholic acid to a similar extent as [3H]triacylglycerol secretion (r = .93, P < .01). Lipid composition of secreted VLDL particles did not change during taurocholic acid-induced suppression. No effects on intracellular apoB, [3H]triacylglycerol, triacylglycerol, and cholesterol mass were observed, nor did taurocholic acid affect protein synthesis, albumin secretion, or lactate dehydrogenase (LDH) release. Cellular cholesteryl ester (CHE) mass, however, was markedly reduced. Our results show that bile acids strongly interfere with the assembly or secretion of VLDL particles by human hepatocytes, suggesting a physiological function of the enterohepatic circulation of bile acids in the regulation of postprandial serum lipid levels.
authors.affiliation: Department of Pediatrics, Groningen Institute for Drug Studies, Academic Hospital Groningen, The Netherlands.
authors.forename: Y
authors.initials: Y
authors.lastname: Lin
authors.forename: R
authors.initials: R
authors.lastname: Havinga
authors.forename: H J
authors.initials: HJ
authors.lastname: Verkade
authors.forename: H
authors.initials: H
authors.lastname: Moshage
authors.forename: M J
authors.initials: MJ
authors.lastname: Slooff
authors.forename: R J
authors.initials: RJ
authors.lastname: Vonk
authors.forename: F
authors.initials: F
authors.lastname: Kuipers
mesh_terms: D000328:Adult; D000368:Aged; D001055:Apolipoproteins B / Q000378:metabolism; D001647:Bile Acids and Salts / Q000494:pharmacology*; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D050356:Lipid Metabolism; D008079:Lipoproteins, VLDL / Q000737:chemistry / Q000378:metabolism*; D008099:Liver / Q000166:cytology / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011506:Proteins / Q000378:metabolism; D013656:Taurocholic Acid / Q000494:pharmacology
chemical_list: D001055:Apolipoproteins B; D001647:Bile Acids and Salts; D008079:Lipoproteins, VLDL; D011506:Proteins; D013656:Taurocholic Acid; D007770:L-Lactate Dehydrogenase